Johnston Erwin
About Johnston Erwin
Chief Executive Officer at TRexBio
Johnston Erwin took on the role of Chief Executive Officer at TRexBio in May 2021. With a wealth of experience from his previous positions at Eli Lilly and Company, he brings a strategic vision and proven leadership skills to TRexBio. As CEO, Erwin is expected to drive growth and innovation, leveraging his extensive background in corporate business development and successful track records in the pharmaceutical industry.
Career at Eli Lilly and Company
Johnston Erwin dedicated 36 years of his career to Eli Lilly and Company, where he worked in various crucial roles. His notable contributions include his service as Vice President of Corporate Business Development for Lilly New Ventures. A significant aspect of his career was leading the clinical team responsible for global regulatory submissions for important drugs such as Evista and Forteo. Under his leadership, both drugs received approval in over 80 countries, achieving blockbuster status with worldwide sales exceeding $1 billion each.
Leadership in Lilly New Ventures
From 2014 until his retirement in 2021, Johnston Erwin led Lilly New Ventures. Under his direction, the venture capital arm's invested capital grew more than five times. Furthermore, Lilly New Ventures was cash-on-cash positive for seven consecutive years, marking a period of significant financial success. Erwin's strategic investments and collaborations significantly contributed to the growth and profitability of Lilly New Ventures.
Experience in Investments and Acquisitions
During his career, Johnston Erwin played a pivotal role in over 10 company acquisitions and the establishment of more than 20 collaborations. He was integral to the founding investment teams and served as an investor or board member for various companies. Upon his retirement from Eli Lilly, he left behind a legacy of over 45 direct investments, showcasing his profound impact on corporate growth and partnerships in the pharmaceutical industry.